Heska Corp (NASDAQ:HSKA) has received a consensus recommendation of “Hold” from the nine analysts that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $105.50.
HSKA has been the subject of several research analyst reports. Sidoti upgraded shares of Heska from a “neutral” rating to a “buy” rating and set a $94.00 target price for the company in a research note on Monday, February 5th. Aegis reiterated a “buy” rating on shares of Heska in a research note on Tuesday, December 19th. Raymond James Financial restated a “buy” rating on shares of Heska in a research note on Monday, December 4th. BidaskClub upgraded shares of Heska from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. Finally, B. Riley restated a “hold” rating and issued a $96.50 price objective on shares of Heska in a research note on Friday, October 27th.
In other news, insider Michael J. Mcginley sold 7,826 shares of the stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $87.14, for a total value of $681,957.64. Following the completion of the transaction, the insider now owns 106,771 shares in the company, valued at approximately $9,304,024.94. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 14.70% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp grew its holdings in shares of Heska by 3.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 100,278 shares of the medical research company’s stock worth $8,834,000 after purchasing an additional 3,610 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Heska by 5.7% in the 2nd quarter. Northern Trust Corp now owns 120,060 shares of the medical research company’s stock worth $12,255,000 after purchasing an additional 6,517 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Heska by 31.7% in the 2nd quarter. Vanguard Group Inc. now owns 461,841 shares of the medical research company’s stock worth $47,141,000 after purchasing an additional 111,232 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Heska by 194.7% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 31,215 shares of the medical research company’s stock worth $2,750,000 after purchasing an additional 20,624 shares during the last quarter. Finally, Atlantic Trust Group LLC bought a new stake in shares of Heska in the 3rd quarter worth about $16,059,000. 80.03% of the stock is currently owned by institutional investors and hedge funds.
Heska (NASDAQ:HSKA) traded down $2.16 during trading hours on Wednesday, reaching $58.36. 110,700 shares of the company traded hands, compared to its average volume of 79,852. The firm has a market cap of $420.48, a PE ratio of 30.72, a P/E/G ratio of 1.57 and a beta of 0.67. Heska has a 1 year low of $56.59 and a 1 year high of $115.00.
TRADEMARK VIOLATION WARNING: “Heska Corp (HSKA) Receives Average Recommendation of “Hold” from Brokerages” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://ledgergazette.com/2018/02/14/heska-corp-hska-receives-average-recommendation-of-hold-from-brokerages.html.
Heska Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.